US Patent

US9555001 — Pharmaceutical composition and uses thereof

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2033-03-06 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions that combine a DPP-4 inhibitor, a SGLT-2 inhibitor, and metformin XR, and their use to treat certain diseases.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Drugs covered by this patent

Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1967`	—	Tradjenta
`U-1968`	—	Tradjenta

Patent Metadata

Patent number: US9555001
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-06
Drug substance claim: No
Drug product claim: Yes
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.